Loteprednol
- Generic Name
- Loteprednol
- Brand Names
- Alrex, Lotemax, Zylet
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27ClO5
- CAS Number
- 129260-79-3
- Unique Ingredient Identifier
- Z8CBU6KR16
- Indication
用于眼科局部炎症。0.2％浓度适用于暂时缓解季节性过敏性结膜炎；0.5％混悬液适用于治疗对类固醇有效的炎症，如结膜炎、角膜、前房炎、过敏性结膜炎、痤疮、酒糟鼻、表浅性点状角膜炎、疱疹、带状疱疹角膜炎、虹膜炎、睫状体炎等可适当减轻水肿和炎症。尚可用于眼科手术后炎症的治疗。
- Associated Conditions
- Chickenpox, Conjunctivitis infective, Cyclitis, Eye infection viral, Herpes Zoster Keratitis, Inflammation, Iritis, Ocular Inflammation, Rosacea, Seasonal Allergic Conjunctivitis, Superficial punctate keratitis
- Associated Therapies
- -
The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT02120079
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
- Conditions
- Interventions
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 102
- Registration Number
- NCT01817582
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Irvine, California, United States
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 75
- Registration Number
- NCT01695668
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
- Conditions
- Interventions
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 60
- Registration Number
- NCT01456780
- Locations
- 🇺🇸
Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, United States
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Innovative Medical
- Target Recruit Count
- 100
- Registration Number
- NCT01193504
- Locations
- 🇺🇸
The Center For Excellence in Eye care, Miami, Florida, United States
🇺🇸Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸Ophthalmic Consultants of Boston, Waltham, Massachusetts, United States
Use of Loteprednol for Contact Lens Intolerance and Dryness
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2009-01-06
- Lead Sponsor
- Hom, Milton M., OD, FAAO
- Target Recruit Count
- 25
- Registration Number
- NCT00817557
- Locations
- 🇺🇸
Milton M. Hom, OD, FAAO., Azusa, California, United States
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- Ophthalmic Consultants of Long Island
- Target Recruit Count
- 5
- Registration Number
- NCT00407043
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, Lynbrook, New York, United States
Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
- Conditions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 40
- Registration Number
- NCT00366691
- Locations
- 🇺🇸
Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.